Novo Nordisk A/S has launched HemaGo XChange, a new web-based service portal for people with bleeding disorders. This platform will address the overwhelming demands that patients with hemophilia might face in the monitoring and sharing of information about their disease.
HemaGo XChange allows patients to monitor and share treatment and bleed data with their healthcare teams in real time.
It is an upgrade that compliments Novo Nordisk’s existing HemaGo mobile app and website, which were created to help people with hemophilia more easily manage the important details of living with the disorder. Since 2012, HemaGo has been helping users monitor, record, and manage their health status, treatment progress, and more from their Apple or Android mobile device or a personal computer.
HemaGo users can track when and how much factor was used in treatments, the type of infusion, vial and dosing amounts, and information about other medications the patient may be taking. They can record type, location, duration, frequency, and status of bleeds, log life experiences such as pain levels and health scores, share how having a bleeding disorder has affected their work, school, or other activities, and upload photos to their bleed log.
HemaGo XChange adds the ability to share data the patient enters into his or her HemaGo diary with the individual’s hemophilia treatment network. Healthcare providers invited by patients to connect via the HemaGo XChange portal will be able to view the data.
Additionally, Novo Nordisk’s U.S. subsidiary Novo Nordisk Inc. and the nonprofit American Thrombosis and Hemostasis Network (ATHN) organization are collaborating to to enable HemaGo XChange users to authorize their data to be entered into ATHN’s national bleeding disorder database. Users opting to do so can submit a request via one of the 135 ATHN-affiliated Hemophilia Treatment Centers (HTCs) across the United States. Through the treatment centers, the ATHN also supports various projects that can benefit from access the organization’s secure data resources to help improve quality of life for people affected by bleeding and blood clotting disorders.
“Hemophilia is a dynamic condition, impacting many areas of a person’s life,” John Spera, vice president, biopharmaceuticals marketing at Novo Nordisk Inc., said in a press release.
“We developed HemaGo XChange to help drive progress in hemophilia management by turning static data into usable information for people with hemophilia, their care teams and even researchers,” he said. “With timely information about the daily experiences of patients, including bleeds, healthcare providers can adjust their care to better fit patient lives.”
According to the National Hemophilia Foundation Fast Facts website, hemophilia is a rare, genetic blood clotting disorder that affects roughly 20,000 people in the U.S. The condition’s demand for ongoing treatment and management, and critical importance of maintaining collaboration and communication between patients and care teams, underscores the value of HemaGo and HemaGo XChange in helping facilitate efficient communication through multiple information sharing channels via the Internet.
Note that Novo Nordisk does not have access to patient-specific information, and is restricted to viewing only de-identified data, the individual sources of which must not be identified, in accordance with privacy and security rules under the HIPAA law.
For more information, visit https://www.hemago.com.